Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03284723
Title PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Pfizer

stomach cancer

Her2-receptor negative breast cancer

Her2-receptor positive breast cancer


Letrozole + Palbociclib + PF-06804103


Age Groups: senior | adult
Covered Countries USA | ITA | ESP

No variant requirements are available.